VolitionRX Limited Common Stock (VNRX)

DALLAS, Texas, Nov. 13, 2026 - VivoSim Labs, Inc. (Nasdaq: VIVS) and Chemveda Life Sciences are moving human-tissue testing earlier in AI-driven drug development. Chemveda designs and synthesizes AI-generated molecules, while VivoSim evaluates their safety, efficacy and mechanism in 3D human liver and intestinal tissue while the compounds can still be redesigned. That timing addresses a central risk of generative drug discovery: its most promising molecules are often entirely new, meaning no human liver or intestine has encountered them before.

Deleveraging and cost cuts reshape the balance sheet as licensing talks advance.

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that it has signed a nonbinding letter of intent (“LOI”) with Denmark-based Missionpharma A/S to explore the development and global commercialization of its prototype lateral flow technology (“LFT”) for detecting NETosis, a process associated with inflammation. The collaboration will initially focus on evaluating the finger-prick diagnostic test for neonatal sepsis, with potential applications in low- and middle-income countries and humanitarian emergency settings. Missionpharma, which supplies healthcare products to United Nations agencies, government health ministries and other institutions, could support low-cost manufacturing, clinical studies and distribution.

VolitionRx Limited (NYSE American: VNRX) announced the official launch of the DETECSEPS project for the early detection of sepsis as part of the DETECSEPS Consortium, which is receiving €6.3 million, or approximately $7.3 million, in French government funding. The project is an initiative of IHU SEPSIS, coordinated and sponsored by Assistance Publique – Hôpitaux de Paris in partnership with Hospices Civils de Lyon, IDS France and Volition. Volition will provide the project’s sole biomarker, Nu.Q NETs, while IDS France will provide its automated analyzer to measure the biomarker.

Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market session. The company's market cap stands at $4.8 million. NewcelX (NASDAQ:NCEL) shares increased by 15.08% to

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced the publication of a peer-reviewed paper reporting that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in patients with sepsis and septic shock. Published in Critical Care Medicine, the study found significantly higher Nu.Q NETs H3.1 levels in septic shock patients than in sepsis patients and a dose-response relationship with acute kidney injury severity, supporting its potential use for risk stratification and early intervention. The journal also published an independent editorial examining H3.1 nucleosomes as a potential marker of NET-mediated organ injury.

Revenue flat as cost cuts narrowed losses and cash strengthened.

On Friday, VolitionRX (AMEX:VNRX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts and

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that results using its lateral flow finger-prick prototype were highly correlated with results from its established automated Nu.Q NETs test in critically ill sepsis patients, supporting the potential expansion of nucleosome testing beyond centralized laboratories. The company said the lateral flow test could enable rapid identification of high-risk patients in emergency rooms or at the bedside, with testing showing a Spearman correlation of 0.85 and Pearson correlation of 0.881 compared with its CE-marked laboratory assay.

VolitionRx Limited (NYSE American: VNRX) announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company said is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (“ctDNA”). According to the publication, the technology addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring. Volition said it is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications.

VolitionRx Limited (NYSE American: VNRX) highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis, while releasing an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter. The company said multiple studies have shown its Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity and provide strong prognostic value for outcomes including organ failure and mortality.

VolitionRx Limited (NYSE American: VNRX) announced the release of a new clinical study demonstrating the prognostic value of its Nu.Q Cancer Assay in patients newly diagnosed with lung cancer. Conducted with researchers and clinicians at France’s Hospices Civils de Lyon, the real-world study found that levels of the assay’s H3K27Me3-nucleosome biomarker were associated with cancer stage, overall survival and progression-free survival, while a prognostic model incorporating the biomarker and clinical factors successfully stratified patients into low- and high-risk mortality groups. The paper is currently under peer review.

VolitionRx Limited (NYSE American: VNRX) announced a collaboration with Sysmex (TYO: 6869) to optimize Volition’s Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The agreement supports Volition’s strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities and installed analyzer base to accelerate development and commercialization.

VolitionRx Limited (NYSE American: VNRX) announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus. The application builds on the company’s existing Nu.Q(R) NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality.